The lack of speech therapists prevents 250 million children with neurodevelopmental disorders from receiving timely and sufficient care. Waiting lists reach 2 years and rehabilitation that follows is spread over 3 years. Mila's objective is to drastically reduce the length of the treatment by increasing the autonomy of the patient through a medical device delivering autonomous and at-home therapy. Our product uses a patented stimulation technology targeting major neurological processing systems. Its first indication is dyslexia and has demonstrated a clinical impact in two months equivalent to one year of normal cognitive development. We partnered with Disney to transform this software-based therapy into an incredible musical video game experience and reduce the drop-out rate to 2% from the usual 40% in pediatrics. Executive team includes Antoine Yuen, former CTO of Bnbsitter (acquired by Checkmyguest), award-winning game developer Sebastien Desarmaux, Pr. David Cohen (head of Child Psychiatry at Pitie-Salpetriere Hospital), Melanie Descamps, PhD (former deputy director of a Canadian private clinic), Johan Insalaco (former head of software-based medical devices of the notified body GMED) and Dominique Leser (former director of Teladoc Health France). Already in commercial partnership with top-tier insurers, we are raising €12 million in Series A to prepare the mass market launch in three strategic countries (FR, US, GER) and broaden the range of diseases we treat. All existing investors (Kurma, BNP, BPI) have renewed their confidence and are eager to to reinvest in this round.
Is this your company?
Something looks off?